remacemide

Remacemide is a low-affinity NMDA antagonist with sodium channel blocking properties. It has been studied for the treatment of acute ischemic stroke, epilepsy, Huntington's disease, and Parkinson's disease.

Doramapimod HCl is the salt form of Doramapimod, a member of the N-pyrazole-N'-naphthly urea class of p38MAPK inhibitors, which binds to the kinase with both slow association and dissociation rates. BIRB -796 has entered clinical trials for the treatment of autoimmune diseases.

Remacemide hydrochloride is a NMDA receptor antagonist.

1,2-diphenylpropan-2-amine 是Remacemide 的（S，R）-异构体单盐酸盐代谢产物。1,2-diphenylpropan-2-amine 具有抗惊厥作用。